Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
generic viagra online
The Use Of Immunofluorescence In Microdissection Testicular Sperm Extraction
UroToday.com - Microdissection testicular sperm extraction is a procedure used to extract sperm from patients with irreversible non-obstructive azospermia. Sperm extracted are then used for in vitro fertilization (IVF). While this technique has improved the sperm retrieval rate compared to other biopsy techniques, sperm are still often not retrieved. The purpose of our research was to develop a technique for identifying small foci of sperm for retrieval for use in IVF.
News of the day
House Dems To Open Hearings Amid Controversy Over Finances, Public Plan
"House Democrats are pushing forward with a partisan health care bill even as a key Senate Democrat labors to achieve an elusive bipartisan compromise on President Barack Obama"s top legislative priority," The Associated Press reports. "The draft legislation, written without Republican help, would require all Americans to purchase health insurance and would put new requirements on employers, too." The House bill was unveiled last week and "is to be weighed in hearings beginning Tuesday."
Mental Health

Exosome Diagnostics And DxS Diagnostic Innovations Collaborate To Develop Blood-Based Tests For Key Cancer Mutations

Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") announced that they will collaborate on the development of blood-based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS" industry leading Scorpions(R) real-time PCR Mutation Test Kits in conjunction with ExosomeDX"s xOS(TM) technology which harvests high-quality nucleic acids from blood exosomes. The collaboration will initially focus on developing blood-based measurement of KRAS, BRAF, EGFR and other key mutations for predicting patient response to targeted therapies. Blood-based mutation measurement is particularly valuable in circumstances where tissue bioavailability is limited such as in lung, pancreatic and ovarian cancers. Exosomes are small microvesicles precipitously shed by all solid tumors into blood. They contain virtually the entire cancer tumor transcriptome. In studies, ExosomeDX has identified most mRNA and miRNA in circulating tumor derived exosomes, all protected in the exosome lipid bi-layer from any blood-based RNase. Initial findings were published in the December 2008 issue of Nature Cell Biology. "There are over 180 companies investigating over 370 different molecular targeted cancer therapies, many of which will require high-quality, molecular companion diagnostics," said James McCullough, Chief Executive Officer Exosome Diagnostics. "Teaming with the world leader in this space is a critical step in providing a solution for pharmaceutical companies, researchers and clinicians to measure the key mutations DxS Scorpion probes target directly from blood." "Combining the ability to pull high-quality mutations from a simple blood draw with the unparalleled sensitivity and specificity of our Scorpion assays will provide our pharmaceutical and research customers with an ideal solution in personalized medicine," said Dr. Stephen Little, Chief Executive Officer of DxS. About DxS DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. Working predominantly in the field of cancer, DxS has a range of companion diagnostic and research kits that detect mutations in oncogenes. About Exosome Diagnostics Exosome Diagnostics is a developer of proprietary non-invasive, molecular diagnostic tests. The company"s core technology is based on discoveries by Harvard and Massachusetts General Hospital researchers that circulating nanovesicles in blood and urine called exosomes contain unique genetic markers that can be reliably harvested for personalized medicine cancer diagnostics Exosome Diagnostics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009